Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert


Search Title by author or title

Standard vs transepithelial collagen cross-linking in management of keratoconus

Poster Details

First Author: S.Shoukry EGYPT

Co Author(s):                        

Abstract Details


To compare and show the difference between corneal biomechanics, endothelial count and stablization after treating keratoconus conditions with corneal collagen cross-linking using either transepithelial or epithelium- off corneal collagen cross linking.


Kobry Al Kobba Military Specialized Eye Hospital


This study is a Single-centre Prospective Interventional Study between March to December 2016 and included 30 eyes at Kobry Al Kobba Military Specialized Eye Hospital. Patients were followed up postoperatively at 1 week, 1 month, 3 months and at 6 months for their uncorrected visual acuity and best corrected visual acuity, refraction, Pentacam, Ocular response analyzer and Specular microscope.


The study included 30 eyes subdivided into 2 groups: Group I: 15 eyes CXL after removal of epithelium. Group II: 15 eyes CXL with epithelium intact The mean preoperative UCVA was 0.208 �Â�± 0.12 while mean postoperative UCVA at one month was 0.217 �Â�± 0.17 At 3 months mean postoperative UCVA was 0.33 �Â�± 0.22 at the 6 months visit was 0.34 �Â�±0.25 mean preoperative BCVA was 0.38 �Â�± 0.15 while mean postoperative BCVA at one month was 0.46 �Â�± 0.2 At 3 months the mean BCVA was 0.58 �Â�± 0.2 at the 6 months visit was 0.62 �Â�± 0.2


Corneal CXL treatment is a minimally invasive procedure aiming at the stabilization of corneal ectatic disorders. From our results we found that six months postoperatively, corneal collagen cross-linking appears to be effective in improving uncorrected and best spectacle-corrected visual acuities. No serious or long term side effects for CXL were encountered in any of our patients.

Financial Disclosure:


Back to Poster listing